Invention Grant
- Patent Title: Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)
-
Application No.: US16641533Application Date: 2018-08-24
-
Publication No.: US11597739B2Publication Date: 2023-03-07
- Inventor: Michel L. Tremblay , Kelly-Anne Pike , Luis Alberto Perez Quintero
- Applicant: The Royal Institution for the Advancement of Learning/McGill University
- Applicant Address: CA Montreal
- Assignee: The Royal Institution for the Advancement of Learning/McGill University
- Current Assignee: The Royal Institution for the Advancement of Learning/McGill University
- Current Assignee Address: CA Montreal
- Agency: Benoit & Cote Inc.
- International Application: PCT/CA2018/051025 WO 20180824
- International Announcement: WO2019/036815 WO 20190228
- Main IPC: C07F9/6553
- IPC: C07F9/6553 ; C12N5/0783
Abstract:
The invention encompasses ex vivo method of stimulating isolated memory T-cell, tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell with compounds of Formula I below, which are inhibitors of the TC-PTP enzyme.
Public/Granted literature
- US20210155645A1 ENHANCING CD8+ T CELLS FOR ADOPTIVE T CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP) Public/Granted day:2021-05-27
Information query
